This phase I/II study is evaluating how safe, tolerable and effective a new cancer drug (AZD8205) is in people with advanced or metastatic solid cancers.
This trial is treating patients with breast cancer, ovarian cancer, bile duct cancer and endometrial cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies
**Update: This trial is currently only recruiting for the Ovarian cohort.**
This study has two parts. Part A (dose escalation) seeks to determine the safety, and what the Recommended Phase 2 Dose (RP2D) and/or the Maximum Tolerated Dose (MTD) of AZD8205 is. All participants will receive AZD8205 alone. Part B (dose expansion) aims to evaluate the anti-cancer effectiveness of AZD8205. Participants with select solid cancers will receive AZD8205 as alone.
Recruiting Hospitals Read More